Expression of somatostatin receptor subtypes 2 and 4 in human benign prostatic hyperplasia and prostatic cancer

The presence of receptor subtypes for the inhibitory peptide somatostatin in prostatic tissue has been a controversial issue with conflicting reports. To elucidate whether prostatic epithelial cells express mRNA for somatostatin receptor (SSTR) subtype 2 and 4, we have investigated the localization of SSTR2 and SSTR4 transcripts in prostatic tissues by in situ hybridization.

[1]  Ramdas,et al.  Effect of isotopic constitution of diamond on its elastic constants: 13C diamond, the hardest known material. , 1993, Physical review letters.

[2]  S. Seino,et al.  Cloning and functional characterization of a family of human and mouse somatostatin receptors expressed in brain, gastrointestinal tract, and kidney. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[3]  J. Logel,et al.  Synthesis of cRNA probes from PCR-generated DNA. , 1992, BioTechniques.

[4]  W. Wahli,et al.  Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat. , 1996, Endocrinology.

[5]  J. Bratlie,et al.  The effect of somatostatin analogue SMS 201-995 on serotonin levels in the medium of primary carcinoid cell cultures. , 1992, Scandinavian journal of gastroenterology.

[6]  U. Kumar,et al.  Subtypes of the Somatostatin Receptor Assemble as Functional Homo- and Heterodimers* , 2000, The Journal of Biological Chemistry.

[7]  J. Reubi,et al.  Somatostatin receptors in human prostate and prostate cancer. , 1995, The Journal of clinical endocrinology and metabolism.

[8]  M. Ranieri,et al.  Modulation of cytokine production in activated human monocytes by somatostatin , 1996, Neuropeptides.

[9]  S. Kato,et al.  Cyclin E as a Coactivator of the Androgen Receptor , 2000, The Journal of cell biology.

[10]  A. Bjartell,et al.  Localization and mRNA expression of somatostatin receptor subtypes in human prostatic tissue and prostate cancer cell lines. , 2002, Urologic oncology.

[11]  L. Rohrer,et al.  Cloning and characterization of a fourth human somatostatin receptor. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[12]  P. Abrahamsson.  Neuroendocrine cells in tumour growth of the prostate. , 1999, Endocrine-related cancer.

[13]  T. Senge,et al.  Inability of complete androgen blockade to increase survival of patients with advanced prostatic cancer as compared to standard hormonal therapy. , 1987, The Journal of urology.

[14]  Thea D. Tlsty,et al.  Normal human mammary epithelial cells spontaneously escape senescence and acquire genomic changes , 2001, Nature.

[15]  P. Santisteban,et al.  Somatostatin Interferes with Thyrotropin-induced G1-S Transition Mediated by cAMP-dependent Protein Kinase and Phosphatidylinositol 3-Kinase , 2000, The Journal of Biological Chemistry.

[16]  J. Simons,et al.  Characterization of the role of IL‐6 in the progression of prostate cancer , 1999, The Prostate.

[17]  M. Houde,et al.  Somatostatin inhibits Akt phosphorylation and cell cycle entry, but not p42/p44 mitogen-activated protein (MAP) kinase activation in normal and tumoral pancreatic acinar cells. , 2001, Endocrinology.

[18]  S. Dunn.  Insulin-like growth factor I stimulate angiogenesis and the production of vascular endothelial growth factor , 2000 .

[19]  M. Thangaraju,et al.  Caspase-8-mediated Intracellular Acidification Precedes Mitochondrial Dysfunction in Somatostatin-induced Apoptosis* , 2000, The Journal of Biological Chemistry.

[20]  S. Falkmer,et al.  Hormones and carcinogenesis , 1998 .

[21]  P. A. Sant'agnese,et al.  Neuroendocrine differentiation in prostatic carcinoma: An update , 1998 .

[22]  H. Stępień,et al.  Effect of somatostatin and octreotide on proliferation and vascular endothelial growth factor secretion from murine endothelial cell line (HECa10) culture. , 2000, Biochemical and biophysical research communications.

[23]  C. Logothetis,et al.  Growth inhibition of human prostatic carcinoma cell lines by serotonin antagonists. , 1994, Anticancer research.

[24]  H. Imura,et al.  Cloning, functional expression and pharmacological characterization of a fourth (hSSTR4) and a fifth (hSSTR5) human somatostatin receptor subtype. , 1993, Biochemical and biophysical research communications.

[25]  D. Hoyer,et al.  Differential expression of five somatostatin receptor subtypes, SSTR1-5, in the CNS and peripheral tissue. , 1994, Digestion.

[26]  H. Klocker,et al.  Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor and epidermal growth factor. , 1995, European urology.

[27]  K. Griffiths,et al.  Androgens, androgen receptors, antiandrogens and the treatment of prostate cancer. , 1997, European urology.

[28]  A. Schally,et al.  Targeted cytotoxic analogue of somatostatin AN-238 inhibits growth of androgen-independent Dunning R-3327-AT-1 prostate cancer in rats at nontoxic doses. , 1998, Cancer research.

[29]  D. Bostwick,et al.  High expression of somatostatin receptors and messenger ribonucleic acid for its receptor subtypes in organ-confined and locally advanced human prostate cancers. , 2000, The Journal of clinical endocrinology and metabolism.

[30]  J. Overgaard,et al.  Association between immunohistochemical expression of vascular endothelial growth factor (VEGF), VEGF-expressing neuroendocrine-differentiated tumor cells, and outcome in prostate cancer patients subjected to watchful waiting. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[31]  U. Kumar,et al.  Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity. , 2000, Science.

[32]  R. Bianchi,et al.  Direct inhibitory effect of somatostatin on the growth of the human prostatic cancer cell line LNCaP: possible mechanism of action. , 1993, The Journal of clinical endocrinology and metabolism.

[33]  A. Hoeflich,et al.  Insulin-like growth factor-I is an autocrine regulator of chromogranin A secretion and growth in human neuroendocrine tumor cells. , 2000, Cancer research.

[34]  T. H. van der Kwast,et al.  Androgen‐independent growth is induced by neuropeptides in human prostate cancer cell lines , 2000, The Prostate.

[35]  C. Robson,et al.  Androgen receptor signalling in the prostate , 2000, BJU international.

[36]  G. Mengod,et al.  Somatostatin receptor subtypes sst1, sst2, sst3 and sst5expression in human pituitary, gastroentero‐pancreatic and mammary tumors , 1997 .

[37]  T. Moody,et al.  Somatostatin inhibits the secretion of bombesin-like peptides from small cell lung cancer cells , 1988, Peptides.

[38]  H. Klocker,et al.  Activation of the androgen receptor by polypeptide growth factors and cellular regulators , 2004, World Journal of Urology.

[39]  Y. Patel.  Somatostatin and Its Receptor Family , 1999, Frontiers in Neuroendocrinology.

[40]  R G Smith,et al.  Rapid identification of subtype-selective agonists of the somatostatin receptor through combinatorial chemistry. , 1998, Science.

[41]  C. Stidsen,et al.  Development of selective antibodies against the human somatostatin receptor subtypes sst1-sst5. , 1997, Brain research. Molecular brain research.

[42]  M. Housset,et al.  Phase I–II study of the somatostatin analogue lanreotide in hormone-refractory prostate cancer , 2004, Cancer Chemotherapy and Pharmacology.

[43]  K. Jensen,et al.  Somatostatin and/or somatostatin-like immunoreactive endocrine-paracrine cells in the human prostate gland. , 1984 .

[44]  S. Nilsson,et al.  [111In-DTPA-D-Phe1]-octreotide scintigraphy in patients with hormone-refractory prostatic adenocarcinoma can predict therapy outcome with octreotide treatment: a pilot study. , 1998, Anticancer research.

[45]  M. Salvatore,et al.  Different expression patterns of somatostatin receptor subtypes in cultured epithelial cells from human normal prostate and prostate cancer. , 1997, The Journal of clinical endocrinology and metabolism.

[46]  A. Schonbrunn.  Somatostatin receptors present knowledge and future directions. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[47]  A. Schally,et al.  sst2 Somatostatin Receptor Mediates Cell Cycle Arrest and Induction of p27 Kip1 , 1999, The Journal of Biological Chemistry.

[48]  S. Seino,et al.  Somatostatin receptors, an expanding gene family: cloning and functional characterization of human SSTR3, a protein coupled to adenylyl cyclase. , 1992, Molecular Endocrinology.